Adverse events1,632

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,632

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Lenvatinib + Pembrolizumab	20	143	24
other	Anaemia	Blood and lymphatic system disorders	SOC Chemotherapy	37	140	40
other	Anaemia	Blood and lymphatic system disorders	Lenvatinib Monotherapy	13	88	18
other	Anaemia	Blood and lymphatic system disorders	SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib	4	61	4
other	Anaemia	Blood and lymphatic system disorders	SOC Chemotherapy Switched Over to Pembrolizumab	0	1	0
other	Anaemia	Blood and lymphatic system disorders	Lenvatinib Switched Over to Pembrolizumab+Lenvatinib	2	18	2
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	Lenvatinib + Pembrolizumab	0	143	0
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	SOC Chemotherapy	0	140	0
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	Lenvatinib Monotherapy	0	88	0
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib	0	61	0
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	SOC Chemotherapy Switched Over to Pembrolizumab	0	1	0
other	Necrotic lymphadenopathy	Blood and lymphatic system disorders	Lenvatinib Switched Over to Pembrolizumab+Lenvatinib	1	18	1
other	Ear pain	Ear and labyrinth disorders	Lenvatinib + Pembrolizumab	2	143	2
other	Ear pain	Ear and labyrinth disorders	SOC Chemotherapy	2	140	2
other	Ear pain	Ear and labyrinth disorders	Lenvatinib Monotherapy	3	88	3
other	Ear pain	Ear and labyrinth disorders	SOC Chemotherapy Switched Over to Pembrolizumab+Lenvatinib	1	61	1
other	Ear pain	Ear and labyrinth disorders	SOC Chemotherapy Switched Over to Pembrolizumab	0	1	0
other	Ear pain	Ear and labyrinth disorders	Lenvatinib Switched Over to Pembrolizumab+Lenvatinib	2	18	2
other	Hypothyroidism	Endocrine disorders	Lenvatinib + Pembrolizumab	49	143	52
other	Hypothyroidism	Endocrine disorders	SOC Chemotherapy	12	140	12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04428151/events

API reference For AI assistants

Adverse events1,632

Sources 3

Read this list from software.